Matt Winkler

Matt Winkler has over three decades of experience in the biotech industry. Matt is currently a board member at Akoya Biosciences, and was previously the chairman and founder of Asuragen. Matt has also founded and been CEO of Ambion, and a board member of Mirna Therapeutics, Inc. and PhyloTech/Second Genome.

Winkler began their career as an instructor for the embryology course at the Marine Biological Laboratory. Matt then became an associate professor at the Department of Zoology at the University of Texas. In 1991, they became an adjunct associate professor at the College of Natural Sciences at the University of Texas, a position they held until 2010.

Winkler has been a pioneer in the field of micro RNA research and has made numerous contributions to the understanding of how these molecules regulate gene expression. Matt has also been instrumental in the development of new technologies for the detection and quantification of micro RNAs.

Matt Winkler earned their B.S. in Genetics from the University of California, Berkeley. Matt then went on to earn their PhD in Zoology from the same school. After completing their doctorates, they did postdoctoral studies in Biological Chemistry at the University of California, Davis.